Hello, and thank you for standing by. Welcome to the Nektar Therapeutics Fourth Quarter 2025 Financial Results Conference Call. [Operator Instructions] Please be advised that today's conference is ...

The singer-songwriter's first nomination hinges on the lasting cultural impact of "The Miseducation of Lauryn Hill," which sold over 20 million copies worldwide and won five Grammys, and influenced ...

Shares of Relmada Therapeutics RLMD rallied 42% in a week after the company announced positive 12-month interim data from its ongoing mid-stage study evaluating NDV-01 in patients with high-risk ...

As FiercePharma explains, the company is attempting to rebrand itself in the wake of a Justice Department investigation, a class-action lawsuit, and a failed attempt at treating Alzheimer’s. Plus: The ...

Alexandria Real Estate Equities, Inc. (NYSE: ARE), the first, preeminent, longest-tenured and pioneering owner, operator and developer of collaborative Megacampus™ ecosystems in AAA ...

Managing complex medical conditions often requires the simultaneous use of multiple different drugs, referred to as polypharmacy. While necessary, this significantly increases the risk of drug-drug ...

For the more than 48 million Americans with substance use disorders, including a disproportionate share of veterans, GLP-1 drugs are not yet an approved addiction treatment. But the evidence base is ...

Plenty of new dramas to enjoy this week, from the return of The Capture and Ellis to a new adaptation of A Woman of Substance – plus Claudia Winkleman hosts her own chatshow in Graham Norton’s slot.

Eli Lilly (LLY) stock under spotlight with $3B China investment, orforglipron approval filing, and LillyConnect platform launch. Analysts maintain bullish outlook.

Yet American health care has in the past proved resistant to treatment from disrupters. In 2008 Google, a search colossus, ...

HIMS stock has staged a sharp rebound after drugmaker Novo Nordisk dropped its lawsuit against the company. Is the stock now a buy?